Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 854

Sort by

Sort Order Select

Journal Articles

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Alexandre Slater, Ying Di, Joanne C. Clark, Natalie J. Jooss, Eleyna M. Martin, Fawaz Alenazy, Mark R. Thomas, Robert A. S. Ariëns, Andrew B. Herr, Natalie S. Poulter, Jonas Emsley, Steve P. Watson

Blood (2021) 137 (24): 3443–3453.

https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Mutational landscape of gray zone lymphoma

Blood (2021) 137 (13): 1765–1776.

https://doi.org/10.1182/blood.2020007507

Published: 2021

Includes: Supplemental data

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

Margaux Lafaurie, PharmD, Bérangère Baricault, Vincent Soler, MD PhD, Myriam Cassagne, MD PhD, Laurent Sailler, MD PhD, Maryse Lapeyre-Mestre, MD PhD, Agnès Sommet, MD PhD, Guillaume Moulis, MD PhD

Blood (2019) 134 (Supplement_1): 2363.

https://doi.org/10.1182/blood-2019-124729

Published: 2019

Journal Articles

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Blood (2019) 134 (Supplement_1): 2426.

https://doi.org/10.1182/blood-2019-129820

Published: 2019

Journal Articles

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

Curtis Marcoux, MD MSc, Shahad Al Ghamdi, MD, Daria Manos, MD, Mary-Margaret Keating, MD, Sudeep P Shivakumar, MD BSc

Blood (2019) 134 (Supplement_1): 2430.

https://doi.org/10.1182/blood-2019-124476

Published: 2019

Journal Articles

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB BS, Katrin Uhlig, MD MS, Megan Lynch, MSN, NP, Li Liu, PhD, Elliott P. Vichinsky, MD

Blood (2019) 134 (Supplement_1): 2249.

https://doi.org/10.1182/blood-2019-123113

Published: 2019

Journal Articles

Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress

Eduard J. van Beers, MD PhD, Malia P. Judge, BS, RN, Lei Hua, PhD, Chris Mix, MD

Blood (2019) 134 (Supplement_1): 4791.

https://doi.org/10.1182/blood-2019-123100

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Jonathan C Poe, PhD, Dadong Zhang, PhD, Jichun Xie, PhD, Rachel A. DiCioccio, BS, Xiaodi Qin, MS, Jiyuan Fang, MS, Vincent T. Ho, MD, Jeremy J. Rose, MS, Steven Z. Pavletic, MD MS, Frances T. Hakim, PhD, Wei Jia, MD PhD, Amy N. Suthers, PhD, Mitchell E. Horwitz, MD, David A. Rizzieri, MD, William C. McManigle, MD, Nelson J. Chao, MD, Kouros Owzar, PhD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 874.

https://doi.org/10.1182/blood-2019-130928

Published: 2019

Journal Articles

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Cris Hanacek, BS, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MDMPH, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 905.

https://doi.org/10.1182/blood-2019-129690

Published: 2019

Journal Articles

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Johanna D Erbani, Joshua Tay, PhD, Valerie Barbier, Masters, Jean-Pierre Levesque, PhD, John L. Magnani, PhD, Ingrid G Winkler, PhD

Blood (2019) 134 (Supplement_1): 907.

https://doi.org/10.1182/blood-2019-132233

Published: 2019

Journal Articles

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Anita Hill, MD PhD, Caroline I. Piatek, Régis Peffault de Latour, MD PhD, Lily LL Wong, MD FRCPath, Richard A. Wells, MD DPhil, Robert A. Brodsky, MD, Jin Seok Kim, MD PhD, Junichi Nishimura, MD PhD, Philip Kuriakose, MD, Rodrigo Pavani, Peng Liu, Stephan Ortiz, RPh, PhD, Hubert Schrezenmeier, MD, Jong-Wook Lee, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 952.

https://doi.org/10.1182/blood-2019-128929

Published: 2019

Journal Articles

Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo

Masashi Miyauchi, Yusuke ITO, MD, Fumio Nakahara, MD PhD, Fumi Nakamura, MD PhD, Yuki Iwasaki, Taiki Kawagoshi, Yuki Kagoya, MD PhD, Shunya Arai, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 720.

https://doi.org/10.1182/blood-2019-126348

Published: 2019

Journal Articles

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Miguel R. Abboud, MD, Jo Howard, MB, BChir, Rodolfo Cançado, Wally R Smith, MD, Birol Güvenç, MD, Noemi Espurz, Marine Weill, Mariane de Montalembert, MD PhD

Blood (2019) 134 (Supplement_1): 998.

https://doi.org/10.1182/blood-2019-125775

Published: 2019

Journal Articles

Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea

Lydia H. Pecker, MD, Eli Salzberg, Shruti Chaturvedi, MBBS, MS, Ni Zhao, MD PhD, Mindy S Christianson, MD MBA, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 890.

https://doi.org/10.1182/blood-2019-122137

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Adrian C. Newland, Blanca Sánchez-González, László Rejtő, Miklos Egyed, Nataliya Romanyuk, Marie Godar, Katrien Verschueren, Domenica Gandini, Peter Ulrichts, Jon Beauchamp, Torsten Dreier, E. Sally Ward, Marc Michel, Howard A. Liebman, Hans De Haard, Nicolas Leupin, David J. Kuter

Blood (2019) 134 (Supplement_1): 895.

https://doi.org/10.1182/blood-2019-128022

Published: 2019

Journal Articles

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Christiane Querfeld, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Lubomir Sokol, MD PhD, Yutaka Tagaya, MD PhD, Paul Frohna, MD PhD PharmD, Nazli Azimi, PhD PharmD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 1557.

https://doi.org/10.1182/blood-2019-129201

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Structural characterization of a novel GPVI-nanobody complex reveals a biologically active domain-swapped GPVI dimer

Mutational landscape of gray zone lymphoma

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

No Increased Risk of Cataract in Immune Thrombocytopenia Adult Patients Treated with Eltrombopag. a French Nationwide Nested Case-Control Study

A Thrombotic Biomarker-Based Risk Assessment Scoring Model for Disease Recurrence in Breast Cancer Patient Candidate to Systemic Chemotherapy

Natural History of Tumor Thrombus: A Single-Centre Retrospective Study

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

CD162 Is a Key E-Selectin Receptor Promoting Acute Myeloid Leukemia Chemo-Resistance in the Bone Marrow Niche

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Genetically Engineered Hematopoietic Progenitors Derived from Human Induced Pluripotent Stem Cells Achieve the Feeder-Free and Robust Production of Neutrophils with the Functional Capacity In Vivo

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Bnz-1, a Selective γ-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: Results of a Multicenter, Open-Label Phase 1 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only